Metronidazole/terconazole - Curatek Pharmaceuticals

Drug Profile

Metronidazole/terconazole - Curatek Pharmaceuticals

Alternative Names: Terconazole/metronidazole

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Curatek Pharmaceuticals
  • Class Antibacterials; Antifungals; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Vaginitis

Most Recent Events

  • 01 Jun 2017 Curatek Pharmaceuticals completes the Trial 1 and Trial 2 SMART GIVES phase III trials for Vaginitis (In adolescents, In adults, In elderly) in USA (Vaginal) (NCT02308046) (NCT02308033)
  • 01 Jun 2015 Phase-III clinical trials in Vaginitis (In adolescents, In adults, In elderly) in USA (Vaginal) (NCT02308007)
  • 01 Jun 2015 Curatek Pharmaceuticals initiates enrolment in the Trial 1 and Trial 2 SMART GIVES phase III trials for Vaginitis (In adolescents, In adults, In elderly) in USA (Vaginal) (NCT02308046, NCT02308033)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top